Protagonist Therapeutics, Inc.

Protagonist Therapeutics Misses on EPS, Stock Down 0.78%

Protagonist Therapeutics reported a loss per share that was slightly worse than expected, contributing to a modest decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's financial outlook. The stock's reaction indicates a cautious sentiment as the company continues to navigate its clinical development efforts.